Recombinant Human Activin Receptor Type IA Protein (Fc Chimera)

Products

Online Inquiry

Recombinant Human Activin Receptor Type IA Protein (Fc Chimera) (RMPP-00230504)

Cat. No.: RMPP-00230504

Category: Growth Factors & Cytokines

Research Area: Cardiovascular

INQUIRY 25 μg Customer Size

Product Features

Source	CHO cells
Purity	> 98% SDS-PAGE. >98% HPLC analyses.
Nature	Recombinant
Endotoxin Level	< 1.000 Eu/µg
Animal Free	No
Form	Lyophilized
Applications	HPLC; SDS-PAGE; Functional Studies
Key Features	Expression system: CHO cells; Purity: > 98% SDS-PAGE; Endotoxin level: < 1.000 Eu/µg; Active: Yes; Suitable for: HPLC, SDS-PAGE, Functional Studies

Protein Information

UniProt ID	P01137
Molecular Weight	25 kDa
Sequence	ALDTNYCFSS TEKNCCVRQL YIDFRKDLGW KWIHEPKGYH ANFCLGPCPY IWSLDTQYSK VLALYNQHNP GASAAPCCVP QALEPLPIVY YVGRKPKVEQ LSNMIVRSCK CSSSALDTNY CFSSTEKNCC VRQLYIDFRK DLGWKWIHEP KGYHANFCLG PCPYIWSLDT QYSKVLALYN QHNPGASAAP CCVPQALEPL PIVYYVGRKP KVEQLSNMIV RSCKCS
Sequence Similarities	Belongs to the TGF-beta family.
Protein Length	Full length protein
Cellular Localization	Secreted > extracellular space > extracellular matrix.
Tissue Specificity	Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage.
Function	Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
Involvement in Disease	Defects in TGFB1 are the cause of Camurati-Engelmann disease (CE); also known as progressive diaphyseal dysplasia 1 (DPD1). CE is an autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.
Post-translational Modifications	Glycosylated.The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.

Storage & Shipping

Shipping and Storage	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. For long term storage it is recommended to add a carrier protein on reconstitution (0.1% HSA or BSA). Working aliquots stored with a carrier protein are stable for at least 3 months at -20°C to -80°C.. This product is an active protein and may elicit a biological response in vivo, handle with caution.

Shipping and Storage

Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. For long term storage it is recommended to add a carrier protein on reconstitution (0.1% HSA or BSA). Working aliquots stored with a carrier protein are stable for at least 3 months at -20°C to -80°C..
This product is an active protein and may elicit a biological response in vivo, handle with caution.

For research use only. Not for clinical use.